Background: Lipopolysaccharide-binding protein (LBP) is essential for the rapid induction of an inflammatory response in the presence of small amounts of lipopolysaccharide (LPS) or Gram-negative bacteria. During Gram-negative bacterial infections, membrane associated LPS, the principal stimulator of the innate immune system, is bound by the acute-phase reactant LBP. Secretion of LBP sensitizes the immune system to endotoxin, enhances the neutralization of endotoxin by high density lipoprotein and, at elevated levels, protects against sepsis. The human LBP sequence consists of a 25-residue signal sequence followed by a 452-residue mature protein containing four cysteine residues and five putative glycosylation sites. During inflammation, LBP is secreted by hepatic cells and intestinal epithelial cells. LPS bound to LBP through lipid A moieties is transferred to LPS receptors (CD14) on the surface of macrophages or to high-density lipoprotein (HDL) particles.
Description: Rabbit polyclonal to LBP
Immunogen: KLH conjugated synthetic peptide derived from LBP
Specificity: ·Reacts with Human, Mouse and Rat.
.·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 53 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
